[go: up one dir, main page]

FI20011664L - Cancerspecifika oligosackaridsekvenser och användning därav - Google Patents

Cancerspecifika oligosackaridsekvenser och användning därav Download PDF

Info

Publication number
FI20011664L
FI20011664L FI20011664A FI20011664A FI20011664L FI 20011664 L FI20011664 L FI 20011664L FI 20011664 A FI20011664 A FI 20011664A FI 20011664 A FI20011664 A FI 20011664A FI 20011664 L FI20011664 L FI 20011664L
Authority
FI
Finland
Prior art keywords
cancer
oligosaccharide sequences
specific oligosaccharide
specific
sequences
Prior art date
Application number
FI20011664A
Other languages
English (en)
Finnish (fi)
Other versions
FI20011664A7 (sv
FI20011664A0 (sv
Inventor
Juhani Saarinen
Jari Helin
Original Assignee
Carbion Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carbion Oy filed Critical Carbion Oy
Priority to FI20011664A priority Critical patent/FI20011664L/sv
Publication of FI20011664A0 publication Critical patent/FI20011664A0/sv
Priority to JP2003521773A priority patent/JP2005500057A/ja
Priority to AU2002319338A priority patent/AU2002319338A1/en
Priority to EP02748913A priority patent/EP1417214A2/en
Priority to PCT/FI2002/000674 priority patent/WO2003016464A2/en
Priority to US10/486,714 priority patent/US8313912B2/en
Publication of FI20011664A7 publication Critical patent/FI20011664A7/sv
Publication of FI20011664L publication Critical patent/FI20011664L/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI20011664A 2001-08-17 2001-08-17 Cancerspecifika oligosackaridsekvenser och användning därav FI20011664L (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FI20011664A FI20011664L (sv) 2001-08-17 2001-08-17 Cancerspecifika oligosackaridsekvenser och användning därav
JP2003521773A JP2005500057A (ja) 2001-08-17 2002-08-16 癌特異的オリゴ糖配列およびその用途
AU2002319338A AU2002319338A1 (en) 2001-08-17 2002-08-16 Cancer specific oligosaccharide sequences and use thereof
EP02748913A EP1417214A2 (en) 2001-08-17 2002-08-16 Cancer specific oligosaccharide sequences and use thereof
PCT/FI2002/000674 WO2003016464A2 (en) 2001-08-17 2002-08-16 Cancer specific oligosaccharide sequences and use thereof
US10/486,714 US8313912B2 (en) 2001-08-17 2002-08-16 Cancer specific oligosaccharide sequences and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20011664A FI20011664L (sv) 2001-08-17 2001-08-17 Cancerspecifika oligosackaridsekvenser och användning därav

Publications (3)

Publication Number Publication Date
FI20011664A0 FI20011664A0 (sv) 2001-08-17
FI20011664A7 FI20011664A7 (sv) 2003-02-18
FI20011664L true FI20011664L (sv) 2003-02-18

Family

ID=8561754

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20011664A FI20011664L (sv) 2001-08-17 2001-08-17 Cancerspecifika oligosackaridsekvenser och användning därav

Country Status (6)

Country Link
US (1) US8313912B2 (sv)
EP (1) EP1417214A2 (sv)
JP (1) JP2005500057A (sv)
AU (1) AU2002319338A1 (sv)
FI (1) FI20011664L (sv)
WO (1) WO2003016464A2 (sv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011671L (sv) * 2001-08-20 2003-02-21 Carbion Oy Tumörspecifika oligosackaridsekvenser och användning därav
AU2002950878A0 (en) * 2002-08-20 2002-09-12 Proteome Systems Intellectual Property Pty Ltd Method for diagnosing disorders
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US7651847B2 (en) 2004-06-22 2010-01-26 The Regents Of The University Of California Methods of oligosaccharide profiling for the detection of cancer
JP2008539412A (ja) * 2005-04-26 2008-11-13 レイモンド， エー． ドウェック， 癌の診断及びモニタリングのためのグリコシル化マーカー
US20060269979A1 (en) * 2005-04-26 2006-11-30 Dwek Raymond A High throughput glycan analysis for diagnosing and monitoring rheumatoid arthritis and other autoimmune diseases
US7892752B2 (en) 2005-04-26 2011-02-22 Dwek Raymond A Glycosylation markers for cancer diagnosing and monitoring
ATE447715T1 (de) * 2005-04-26 2009-11-15 Nat Inst For Bioproc Res And T Automatische glykofingerabdruck-strategie
US8039208B2 (en) * 2005-04-26 2011-10-18 National Institute For Bioprocessing Research And Training Limited (Nibrt) Automated strategy for identifying physiological glycosylation markers(s)
FI20055398A0 (sv) 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Förfarande för att evaluera cellpopulationer
WO2007006870A2 (en) 2005-07-11 2007-01-18 Suomen Punainen Risti, Veripalvelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
FI20055417A0 (sv) * 2005-07-20 2005-07-20 Glykos Finland Oy Cancerspecifika glykaner och deras användning
US7981625B2 (en) 2008-04-15 2011-07-19 The Board Of Trustees Of The Leland Stanford Junior University Prostate cancer glycan markers and autoantibody signatures
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
US20110236995A1 (en) * 2008-12-03 2011-09-29 The Noguchi Institute Method for determining prostate cancer
JP5443156B2 (ja) * 2009-12-28 2014-03-19 公益財団法人野口研究所 前立腺癌を判定する方法
GB201705686D0 (en) 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
EP3819639B1 (en) * 2018-07-11 2023-11-08 Japanese Foundation For Cancer Research Sugar chain specific to prostate cancer, and test method using same
KR102874614B1 (ko) * 2018-11-08 2025-10-22 디에스엠 아이피 어셋츠 비.브이. 위장 대사물질을 조절하는 방법
AU2019376668B2 (en) * 2018-11-08 2024-12-05 Dsm Ip Assets, B.V. Methods of selectively modulating gastrointestinal microbial growth
CN112129938B (zh) * 2019-06-25 2023-08-18 中国科学院分子细胞科学卓越创新中心 UDP-Glc在肺癌转移评估中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2114287B (en) * 1982-01-29 1985-10-30 Otsuka Pharma Co Ltd Process for determining tumor-associated glycolinkage
US4904596A (en) 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
US5660834A (en) 1988-03-11 1997-08-26 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with carbohydrate-carrier conjugates
JPH07504222A (ja) * 1992-02-19 1995-05-11 ザ・バイオメンブレイン・インスティテュート 化学的に規定されるオリゴ糖，該オリゴ糖の誘導体，擬態物及び該オリゴ糖に対する抗体による細胞接着の抑制
CZ39093A3 (en) * 1992-03-12 1994-03-16 Lilly Co Eli Oligosaccharide and pharmaceutical preparation in which it is comprised
WO1997028174A1 (en) * 1996-01-30 1997-08-07 Novartis Ag SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES
US5972907A (en) * 1997-10-31 1999-10-26 Health Research, Inc. Synthetic core 2-like branched structures containing GalNAc-lewisx and Neu5Acα2-3Galβ1-3GalNAc sequences as novel ligands for selectins
AU5928999A (en) * 1998-09-21 2000-04-10 Richard D. Cummings Assays for helminth infections
JPWO2002077649A1 (ja) * 2001-03-27 2004-07-15 帝国臓器製薬株式会社 乳癌診断法
EP1639090A4 (en) * 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER

Also Published As

Publication number Publication date
FI20011664A7 (sv) 2003-02-18
EP1417214A2 (en) 2004-05-12
US8313912B2 (en) 2012-11-20
AU2002319338A1 (en) 2003-03-03
US20040253651A1 (en) 2004-12-16
WO2003016464A2 (en) 2003-02-27
WO2003016464A3 (en) 2003-05-22
FI20011664A0 (sv) 2001-08-17
JP2005500057A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
FI20011664L (sv) Cancerspecifika oligosackaridsekvenser och användning därav
FI20011671L (sv) Tumörspecifika oligosackaridsekvenser och användning därav
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
EP1298180A4 (en) HYDROPHOBIC AND LIPOPHOBE COMPOSITION
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
DK3266791T3 (da) Mærkede nukleotider
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
EP1379042A4 (en) MULTIPLEXER
DE50106015D1 (de) Osteosynthesemittel
DE60223576D1 (de) Hautbehandlungszusammensetzung
DE60225985D1 (de) Dentaleinheit
DE50209245D1 (de) Neuroprotektives medikament
DE60114244D1 (de) Osteosynthesevorrichtung
DE60220799D1 (de) Hypoglykämisches mittel
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
DE60136966D1 (de) Pflanzenstärkendes mittel
DE60219418T8 (de) Silanylphenole und -naphthole
DE50110467D1 (de) Staffelei
FI20012608A0 (sv) Diagnostiska förfaranden
DK1427748T3 (da) 17alfa-hydroxy-14beta-steroider med hormonal virkning
DE60204435D1 (de) Spritze
DE60206034D1 (de) Spritze
SE0100590D0 (sv) New composition and use
SE0104404D0 (sv) New methods and use

Legal Events

Date Code Title Description
MA Patent expired